Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Registration Now Open for Tribe Public's Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

GlobeNewswire August 22, 2022

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

GlobeNewswire August 18, 2022

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2022

Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy Volunteers

GlobeNewswire July 28, 2022

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

GlobeNewswire June 2, 2022

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

GlobeNewswire May 18, 2022

Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2022

Atossa Therapeutics to Present at the Q2 Investor Summit Conference

GlobeNewswire April 27, 2022

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

GlobeNewswire April 20, 2022

Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

GlobeNewswire March 23, 2022

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

GlobeNewswire March 8, 2022

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

GlobeNewswire February 28, 2022

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

GlobeNewswire January 27, 2022

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

GlobeNewswire January 18, 2022

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

GlobeNewswire December 22, 2021

Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur

PR Newswire December 16, 2021

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

GlobeNewswire December 6, 2021

Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 "A Town Hall Q&A Event With Atossa Therapeutics Management Team"

GlobeNewswire November 24, 2021

Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2021

Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month

GlobeNewswire October 21, 2021